Strategic Collaborations

We are collaborating with leading biopharmaceutical companies to apply our DCE Platform® to existing compounds with known therapeutic properties, including approved drugs, advanced clinical candidates or previously studied biologically active compounds. In these collaborative programs, incorporating deuterium may enable superior pharmacokinetic or metabolic properties and thereby offer the potential opportunity for best-in-class products with enhanced clinical safety, tolerability or efficacy.

Our clinical pipeline of drug candidates resulting from our DCE Platform includes novel drugs that are being developed with strategic collaborators, which include the following:

Under our license agreement, Avanir is developing AVP-786, which combines deuterium-substituted dextromethorphan and an ultra-low dose of quinidine. Avanir is conducting several Phase 2 and Phase 3 clinical trials to evaluate AVP-786 for the treatment of neurologic and psychiatric disorders, the most advanced of which are Phase 3 clinical trials for the treatment of agitation associated with Alzheimer’s disease.
Jazz Pharmaceuticals’ current once-nightly development efforts are focused on lower sodium compounds. The collaboration with Jazz Pharmaceuticals provides for the evaluation of deuterium as an option for a once nightly sodium oxybate product.
Celgene and Concert are collaborating to develop CTP-730, a product candidate containing deuterated apremilast for the treatment of inflammatory diseases. Concert has completed Phase 1 evaluation of CTP-730. Celgene is currently assessing the data from the Phase 1 program.
Under a license agreement, Cipla Technologies has worldwide rights to develop and commercial CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator. Building on Concert’s initial preclinical and clinical evaluation, Cipla intends to develop CTP-354 for the treatment of spasticity and other CNS disorders.
Under a license agreement, Processa Pharmaceuticals has worldwide rights to develop and commercialize CTP-499, a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine, an active metabolite of pentoxifylline.

Asset Purchase Agreement

Under an asset purchase agreement, Vertex acquired worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis. Concert received $160 million in cash upon closing the asset purchase agreement and is eligible to receive up to $90 million in additional milestones.

For partnership inquiries, please contact:
BD@concertpharma.com

Back to Top